Index S&P 500
P/E -
EPS (ttm) -9.79
Insider Own 9.99%
Shs Outstand 255.29M
Perf Week 11.90%
Market Cap 24.80B
Forward P/E 22.79
EPS next Y 4.26
Insider Trans 0.00%
Shs Float 229.84M
Perf Month 12.69%
Income -2495.00M
PEG -
EPS next Q 0.98
Inst Own 87.96%
Short Float 2.32%
Perf Quarter 20.66%
Sales 11.35B
P/S 2.19
EPS this Y 17.44%
Inst Trans -0.77%
Short Ratio 2.31
Perf Half Y 35.69%
Book/sh 55.97
P/B 1.74
EPS next Y 8.65%
ROA -7.55%
Short Interest 5.32M
Perf Year 7.56%
Cash/sh 2.89
P/C 33.57
EPS next 5Y 12.15%
ROE -15.57%
52W Range 62.11 - 97.35
Perf YTD 19.97%
Dividend Est. 1.80 (1.86%)
P/FCF 25.70
EPS past 5Y -
ROI -10.36%
52W High -0.22%
Beta 1.27
Dividend TTM 2.83 (2.91%)
Quick Ratio 1.05
Sales past 5Y 31.28%
Gross Margin 26.99%
52W Low 56.40%
ATR (14) 2.25
Dividend Ex-Date Jun 21, 2024
Current Ratio 1.68
EPS Y/Y TTM -19.21%
Oper. Margin 7.41%
RSI (14) 78.33
Volatility 2.93% 2.35%
Employees 21500
Debt/Eq 0.77
Sales Y/Y TTM -7.27%
Profit Margin -21.98%
Recom 2.42
Target Price 95.20
Option/Short Yes / Yes
LT Debt/Eq 0.69
EPS Q/Q 764.02%
Payout -
Rel Volume 0.56
Prev Close 97.23
Sales Surprise 4.35%
EPS Surprise 31.66%
Sales Q/Q -4.23%
Earnings May 06 AMC
Avg Volume 2.31M
Price 97.14
SMA20 13.04%
SMA50 16.38%
SMA200 27.45%
Trades
Volume 1,263,836
Change -0.09%
Date
Action
Analyst
Rating Change
Price Target Change
May-08-24 Upgrade
JP Morgan
Neutral → Overweight
$75 → $100
Apr-18-24 Upgrade
Barclays
Underweight → Equal Weight
Apr-10-24 Upgrade
Citigroup
Neutral → Buy
$81 → $100
Mar-08-24 Downgrade
Argus
Buy → Hold
Mar-01-24 Initiated
Wolfe Research
Underperform
Jan-22-24 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$81 → $90
Jan-12-24 Upgrade
Jefferies
Hold → Buy
$73 → $112
Nov-28-23 Upgrade
Argus
Hold → Buy
Nov-13-23 Downgrade
UBS
Buy → Neutral
$88 → $78
Oct-12-23 Initiated
Redburn Atlantic
Neutral
$60
Aug-24-23 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$112 → $75
Aug-09-23 Downgrade
Goldman
Buy → Neutral
$120 → $78
Aug-08-23 Downgrade
Stifel
Buy → Hold
$123 → $85
Aug-08-23 Downgrade
Societe Generale
Buy → Hold
$80
Jun-14-23 Initiated
Citigroup
Neutral
$84
Feb-10-23 Upgrade
BofA Securities
Underperform → Neutral
$121 → $106
Jan-11-23 Downgrade
BofA Securities
Buy → Underperform
$121
Nov-09-22 Downgrade
JP Morgan
Overweight → Neutral
$125 → $96
Jun-27-22 Initiated
Credit Suisse
Outperform
$145
Jun-16-22 Downgrade
Jefferies
Buy → Hold
$170 → $101
Show Previous Ratings
Today 06:43AM
May-08-24 03:30PM
11:18AM
11:11AM
08:34AM
08:05AM
Loading…
08:05AM
07:36AM
07:00AM
06:52AM
06:52AM
06:52AM
05:44AM
03:21AM
01:06AM
May-07-24 11:13PM
(Thomson Reuters StreetEvents) +6.40%
04:48PM
Loading…
04:48PM
12:47PM
12:42PM
10:29AM
07:43AM
07:39AM
May-06-24 06:12PM
06:00PM
05:55PM
05:30PM
04:58PM
04:38PM
(Associated Press Finance)
04:16PM
04:15PM
May-03-24 08:42AM
09:00AM
Loading…
May-02-24 09:00AM
May-01-24 04:15PM
12:15PM
09:15AM
Apr-29-24 10:00AM
09:00AM
Apr-16-24 04:15PM
Apr-03-24 01:07PM
12:47AM
12:00AM
Mar-28-24 01:38PM
Mar-25-24 08:00PM
Mar-21-24 06:45AM
Mar-20-24 01:59PM
07:04AM
Mar-19-24 12:21PM
06:59AM
06:52AM
06:45AM
Mar-13-24 07:43PM
Mar-11-24 01:01PM
Mar-04-24 03:00AM
Mar-01-24 04:15PM
Feb-29-24 04:15PM
12:01AM
Feb-28-24 08:06PM
07:00AM
Feb-22-24 10:01AM
05:40AM
Feb-21-24 11:14PM
(Thomson Reuters StreetEvents) -6.40%
12:06PM
11:24AM
Feb-20-24 06:00PM
04:52PM
04:39PM
(Associated Press Finance)
04:15PM
11:21AM
Feb-16-24 12:01PM
Feb-15-24 04:00AM
Feb-14-24 09:15AM
Feb-13-24 06:15PM
Feb-06-24 10:19PM
Feb-05-24 06:15PM
Jan-29-24 06:15PM
Jan-24-24 04:15PM
Jan-19-24 06:55AM
Jan-15-24 01:14AM
Jan-11-24 06:23PM
05:10PM
(The Wall Street Journal)
04:15PM
Dec-26-23 07:48PM
05:02AM
Dec-20-23 11:36AM
Dec-19-23 10:00AM
03:00AM
Dec-08-23 11:24AM
Dec-07-23 12:03PM
Dec-06-23 11:30AM
Nov-21-23 06:22PM
Nov-16-23 09:00AM
Nov-08-23 10:00PM
02:48PM
01:50AM
(Thomson Reuters StreetEvents)
Nov-07-23 02:05PM
01:04PM
11:08AM
Nov-06-23 06:30PM
05:50PM
05:17PM
05:14PM
International Flavors & Fragrances, Inc. engages in the manufacture and supply of flavors and fragrances used in the food, beverage, personal care, and household products industries. It operates through the following segments: Nourish, Health & Biosciences, Scent and Pharma Solutions. The Nourish segment consists of legacy Taste segment combined with N&B's Food & Beverage division and the food protection business of N&B's Health & Biosciences division. The Health & Biosciences business consists of a biotechnology-driven portfolio of enzymes, food cultures, probiotics and specialty ingredients for food, home and personal care, and health and wellness applications. The Scent business creates fragrance compounds, fragrance ingredients and cosmetic ingredients that are integral elements in the world's finest perfumes and best-known household and personal care products. The Pharma Solutions business produces a vast portfolio including cellulosics and seaweed-based pharma excipients, used to improve the functionality and delivery of active pharmaceutical ingredients, including controlled or modified drug release formulations, and enabling. The company was founded in 1833 and is headquartered in New York, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Teles de Mendonca Ana Paula President, Scent May 06 '24 Option Exercise 0.00 726 0 1,178 May 07 07:06 PM RICHTER GLENN R CFO May 03 '24 Option Exercise 0.00 4,243 0 21,889 May 07 07:06 PM Teles de Mendonca Ana Paula President, Scent May 03 '24 Option Exercise 0.00 707 0 707 May 07 07:06 PM Strzelecki Angela President, Pharma Solutions May 03 '24 Option Exercise 0.00 1,060 0 8,868 May 07 07:06 PM O'Byrne Kevin Director May 03 '24 Option Exercise 0.00 1,671 0 1,933 May 07 07:06 PM Yildiz Beril CAO, SVP & Controller May 03 '24 Option Exercise 0.00 848 0 1,588 May 07 07:06 PM Gold Christina A Director May 03 '24 Option Exercise 0.00 1,671 0 10,840 May 07 07:03 PM Herriott Simon Pres. Health & Bioscience May 03 '24 Option Exercise 0.00 1,591 0 10,625 May 07 07:03 PM Hu Gaoxiang Director May 03 '24 Option Exercise 0.00 1,671 0 2,105 May 07 07:04 PM Johnson Jennifer Amy EVP, General Counsel May 03 '24 Option Exercise 0.00 2,121 0 7,936 May 07 07:04 PM Finzel Ralf EVP, Global Operations Officer May 03 '24 Option Exercise 0.00 1,326 0 4,770 May 07 07:03 PM DAVIDSON CAROL ANTHONY Director May 03 '24 Option Exercise 0.00 1,671 0 1,926 May 07 06:56 PM Ferguson Roger W. Jr. Director May 03 '24 Option Exercise 0.00 2,625 0 2,625 May 07 06:56 PM Bruno Barry A. Director May 03 '24 Option Exercise 0.00 1,671 0 3,205 May 07 06:55 PM Costa Mark J Director May 03 '24 Option Exercise 0.00 1,671 0 2,139 May 07 06:55 PM Borg Deborah EVP, Chief HR and D&I Officer May 03 '24 Option Exercise 0.00 1,768 0 17,188 May 07 06:55 PM Arora Yuvraj President, Nourish May 03 '24 Option Exercise 0.00 11,538 0 11,538 May 07 06:54 PM Johnson Jennifer Amy EVP, General Counsel Apr 05 '24 Option Exercise 0.00 968 0 6,165 Apr 09 05:28 PM Herriott Simon Pres. Health & Biosci. & Scent Apr 05 '24 Option Exercise 0.00 1,590 0 9,496 Apr 09 05:26 PM Strzelecki Angela President, Pharma Solutions Apr 05 '24 Option Exercise 0.00 1,140 0 8,162 Apr 09 05:25 PM Herriott Simon Pres. Health & Biosci. & Scent Apr 01 '24 Option Exercise 0.00 1,489 0 8,367 Apr 03 04:24 PM Clyburn Frank Chief Executive Officer Mar 01 '24 Option Exercise 0.00 1,324 0 2,170 Mar 05 07:06 PM Strzelecki Angela President, Pharma Solutions Jan 03 '24 Option Exercise 0.00 1,341 0 7,418 Jan 04 04:06 PM Finzel Ralf EVP, Global Operations Officer Dec 01 '23 Option Exercise 0.00 5,387 0 5,387 Dec 04 04:17 PM Johnson Jennifer Amy EVP, General Counsel Nov 01 '23 Option Exercise 0.00 1,041 0 5,459 Nov 03 04:12 PM Yildiz Beril CAO, SVP & Controller Oct 03 '23 Option Exercise 0.00 1,077 0 1,077 Oct 05 04:09 PM RICHTER GLENN R CFO Oct 02 '23 Option Exercise 0.00 11,812 0 23,624 Oct 04 04:08 PM Borg Deborah EVP, Chief HR and D&I Officer Sep 01 '23 Option Exercise 0.00 27,614 0 27,614 Sep 06 05:24 PM Fauchon de Villeplee Christoph President, Scent May 11 '23 Sale 86.35 1,972 170,282 9,093 May 12 04:17 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite